Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | TTR | P02766 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | TPMT | P51580 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SELL | P14151 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SELP | P16109 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25188688 | 0.83 | MEN1 (0.54) | KDM4EALDH1A1LMNATDP1MEN1 | |
| SCHEMBL8908305 | 0.80 | TPMT (0.37) | TSHRALOX15HIF1ATPMTALDH1A1 | |
| SCHEMBL30412517 | 0.80 | BRD4 (0.40) | TSHRLMNAMAPTSMN1; SMN2HSD17B10 | |
| SCHEMBL16369830 | 0.79 | TSHR (0.50) | TSHRALOX15HIF1ATTRCA12 | |
| SCHEMBL17987756 | 0.78 | KDM4E (0.34) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17670461 | 0.77 | TSHR (0.48) | TSHRALOX15HIF1ATTRCA12 | |
| SCHEMBL1424790 | 0.77 | ALOX15 (0.48) | TSHRALOX15HIF1ACA12CA1 | |
| Hydrochloric Acid SCHEMBL1425679 | 0.76 | ALOX15 (0.46) | TSHRALOX15HIF1ACA12CA1 | |
| SCHEMBL28331934 | 0.75 | KDM4C (0.55) | KDM4EALDH1A1MAPTNAPRT | |
| SCHEMBL30560163 | 0.75 | KDM4C (0.55) | KDM4EALDH1A1MAPTNAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240342301-A1 | ANTIBODY-DRUG CONJUGATES | MC SAF (FR) | 2024-10-17 | — | — | US | disclosed |
| CN-118251239-A | Antibody-drug conjugates | MC SAF公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-4380625-A1 | ANTIBODY-DRUG CONJUGATES | Mc SAF (FR) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023012437-A1 | ANTIBODY-DRUG CONJUGATES | MC SAF (FR) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023012437-A1 | ANTIBODY-DRUG CONJUGATES | MC SAF (FR) | 2023-02-09 | — | — | WO | disclosed |
| US-11278627-B2 | Antibody-drug conjugates and the use of same in therapy | MC SAF (FR) | 2022-03-22 | — | — | US | disclosed |
| EP-3825304-A1 | ANTIBODY-DRUG CONJUGATES AND THE USE OF SAME IN THERAPY | Mc SAF (FR) | 2021-05-26 | — | — | EP | disclosed |
| EP-3825304-A1 | ANTIBODY-DRUG CONJUGATES AND THE USE OF SAME IN THERAPY | Mc SAF (FR) | 2021-05-26 | — | — | EP | disclosed |
| EP-3521314-B1 | ANTIBODY-DRUG CONJUGATES AND USE THEREOF IN THERAPY | MC SAF (FR) | 2021-02-24 | — | — | EP | disclosed |
| EP-3521314-B1 | ANTIBODY-DRUG CONJUGATES AND USE THEREOF IN THERAPY | MC SAF (FR) | 2021-02-24 | — | — | EP | disclosed |
| EP-3521314-A1 | NEW ANTIBODY-DRUG CONJUGATES AND USE THEREOF IN TREATMENT | Université François Rabelais (FR) | 2019-08-07 | — | — | EP | disclosed |
| EP-3521314-A1 | NEW ANTIBODY-DRUG CONJUGATES AND USE THEREOF IN TREATMENT | Université François Rabelais (FR) | 2019-08-07 | — | — | EP | disclosed |
| US-10307488-B2 | Antibody-drug conjugates and the use of same in therapy | UNIVERSITE FRANCOIS RABELAIS (FR) | 2019-06-04 | — | — | US | disclosed |
| US-20160151515-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND THE USE OF SAME IN THERAPY | MC SAF (FR) | 2016-06-02 | — | — | US | disclosed |
| US-20160151515-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND THE USE OF SAME IN THERAPY | MC SAF (FR) | 2016-06-02 | — | — | US | disclosed |
| US-20160151515-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND THE USE OF SAME IN THERAPY | MC SAF (FR) | 2016-06-02 | — | — | US | disclosed |
| EP-3019202-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND THE USE OF SAME IN THERAPY | Université François Rabelais (FR) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015004400-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND THE USE OF SAME IN THERAPY | UNIVERSITE FRANCOIS RABELAIS (FR) | 2015-01-15 | — | — | WO | disclosed |
| WO-2015004400-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND THE USE OF SAME IN THERAPY | UNIVERSITE FRANCOIS RABELAIS (FR) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240342301-A1 | ANTIBODY-DRUG CONJUGATES | FCGRT, FCGR3B, FCGR2A | TSHR 1462/4885ALOX15 3253/4885HIF1A 2522/4885 |
| US-10307488-B2 | Antibody-drug conjugates and the use of same in therapy | CD47, TNFRSF9, VSIG8 | TSHR 3329/4885ALOX15 2408/4885HIF1A 3064/4885 |
| US-20160151515-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND THE USE OF SAME IN THERAPY | CD47, TNFRSF9, VSIG8 | TSHR 3396/4885ALOX15 2490/4885HIF1A 3422/4885 |
| US-11278627-B2 | Antibody-drug conjugates and the use of same in therapy | CD47, TNFRSF9, VSIG8 | TSHR 3329/4885ALOX15 2408/4885HIF1A 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.